The Southwest Oncology Group is a major multi-disease, multi- disciplinary, multi-institution group engaged in cooperative cancer research. This organization now consists of 34 Member Institutions, 26 Community Clinical Oncology Programs (CCOPs), 291 Cooperative Group outreach Programs (CGOPs), 23 Urologic Cancer Outreach Programs (UCOPs) and 26 High Priority affiliates, who accrue approximately 8700 patients to clinical trials each year. Currently there are approximately 100 studies open for accrual in 14 committees. The Statistical Center is essential to the design, conduct, and analysis of the cancer research in the Southwest oncology Group. Its main functions are: to participate in the review of proposed protocols, particularly as regards experimental design, sample size, and feasibility; to provide for central registration of all patients on all studies, and for randomization where appropriate; to provide for review and quality control of data collected during studies; to provide for data entry and for computer processing, storage and retrieval of data; to work with the Group chair and other investigators in the Group to improve the quality of clinical trials through improved forms, more uniform and reproducible data definitions, and more economical flow of data; to help the Group chair in the administration of the Group; to analyze and publish the results of studies in conjunction with the study coordinator; to use the data being collected to try to find new leads regarding prognostic factors and late effects; and to perform statistical research on the efficient design, conduct and analysis of cancer clinical trials and cancer control research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA038926-08
Application #
3558233
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1985-01-01
Project End
1997-12-31
Budget Start
1993-02-01
Budget End
1993-12-31
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Dai, James Y; Liang, C Jason; LeBlanc, Michael et al. (2018) Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 74:753-763
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696
Unger, Joseph M; Griffin, Katherine; Donaldson, Gary W et al. (2017) Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2:27
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80
Cesano, Alessandra; Willman, Cheryl L; Kopecky, Kenneth J et al. (2015) Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 10:e0118485

Showing the most recent 10 out of 512 publications